Marco Timmers has been appointed as chief executive officer of Sapreme which also moved Jeanne Bolger from member to chair of the biotech’s board of directors. The company, which develops RNA therapeutics for genetic diseases, has also established a scientific advisory board of four members to guide Sapreme’s preclinical candidates toward clinical proof-of-concept. The new CEO brings 25 years’ experience in pharmaceutical R&D and before joining Sapreme was CEO of Byondis (formerly Synthon Biopharmaceuticals). Dr Timmers holds a MSc and a PhD in bio-organic chemistry from Leiden University, The Netherlands.
Sapreme announced the appointments on 28 May 2024.
Copyright 2024 Evernow Publishing Ltd